BioCentury | Mar 2, 2018
Product R&D

Sigma for synapses

...study in AD patients showed CT1812 decreased CSF levels of synaptic damage markers neurogranin and synaptotagmin-1...
BioCentury | Nov 10, 2017
Clinical News

Cognition's CT1812 well tolerated in Phase Ib/IIa trial for AD

...CT1812 and placebo arms. Cognition also said that CT1812 led to a “marked reduction” in synaptotagmin-1...
BioCentury | Oct 13, 2017
Clinical News

FDA approves once-daily dosing for Orfadin

FDA approved a once-daily dosing regimen for Orfadin nitisinone oral suspension and oral capsules from Swedish Orphan Biovitrum AB (SSE:SOBI) to treat hereditary tyrosinemia type I in patients ages ≥5 who have undetectable serum and...
BioCentury | Aug 3, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Patient sample, cell culture and mouse studies suggest inhibiting SYNCRIP could help treat AML. In bone marrow samples from patients, SYNCRIP levels were higher than in hematopoietic stem and progenitor...
BioCentury | Jul 21, 2016
Translation in Brief

Survival of the modified

A selection strategy commonly used to clone cells in vitro has been co-opted by a group at Oregon Health & Science University to create a gene therapy platform that gives a proliferation advantage to cells...
BioCentury | May 2, 2016
Clinical News

Nitisinone oral suspension regulatory update

FDA approved an NDA from Swedish Orphan for an oral suspension formulation of Orfadin nitisinone to treat hereditary tyrosinemia type I, a rare genetic disorder that can cause liver failure, kidney dysfunction and neurological problems....
BioCentury | Sep 21, 2015
Clinical News

Oral suspension Orfadin nitisinone regulatory update

FDA accepted for review an NDA from Swedish Orphan for an oral suspension formulation of Orfadin nitisinone to treat hereditary tyrosinaemia type I, a rare genetic disorder that can cause liver failure, kidney dysfunction and...
BioCentury | Jul 13, 2015
Clinical News

Oral suspension Orfadin nitisinone regulatory update

The European Commission approved an oral suspension formulation of Orfadin nitisinone from Swedish Orphan to treat hereditary tyrosinaemia type I, a rare genetic disorder that can cause liver failure, kidney dysfunction and neurological problems. The...
BioCentury | Mar 31, 2014
Finance

LSP's steady hand

When LSP-Life Sciences Partners launches a new healthcare venture fund next year it will stick to a strategy that has yielded 12 exits in the past 18 months - early stage, European drug development companies. The...
Items per page:
1 - 10 of 81